BiotechTube
AxisPharm

AxisPharm

San Diego, United States· Est.
axispharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

AxisPharm is a specialized CRO/CDMO focusing on the high-growth niche of bioconjugation, particularly for antibody-drug conjugates (ADCs) and advanced drug delivery systems. The company operates a dual business model, offering both high-purity chemical reagents (like linkers, PEGs, and fluorescent probes) and a comprehensive suite of analytical development services powered by advanced mass spectrometry. Positioned in San Diego's biotech hub, AxisPharm caters to the outsourced R&D needs of emerging and established biopharma companies, providing critical tools and data to accelerate therapeutic development from discovery through preclinical stages.

Drug Delivery

Technology Platform

Integrated platform combining proprietary bioconjugation chemistry (specializing in PEG linkers, ADC linkers/payloads, fluorescent probes) with advanced mass spectrometry-based analytical services (proteomics, metabolomics, bioanalytical PK) for drug discovery and development support.

Opportunities

The rapid growth of the ADC and targeted therapy market drives demand for specialized bioconjugation expertise and analytical services.
AxisPharm can expand by moving into GMP-grade manufacturing of linkers/payloads and forming deeper, integrated partnerships with ADC developers.
Its dual product-and-service model creates multiple revenue streams from a single client base.

Risk Factors

Faces intense competition from large CROs and reagent suppliers.
Revenue is tied to biotech R&D funding cycles, making it vulnerable to sector downturns.
Requires continuous high capital investment in advanced instrumentation to maintain technological competitiveness, posing a financial and operational challenge.

Competitive Landscape

AxisPharm competes in specialized segments against large, diversified CROs (e.g., LabCorp, IQVIA) and reagent suppliers (e.g., Thermo Fisher), as well as smaller niche players in ADC services (e.g., Abzena, Cerbios-Pharma) and analytical CROs. Its differentiation lies in the tight integration of its proprietary chemical toolbox with its analytical service capabilities, offering a 'one-stop-shop' for bioconjugation development and characterization.

More companies in Antibody-Drug Conjugates →More companies in United States →